Elektronisk verifisering av legemiddelpakninger og status i Norge. Eckart Holtz 22.September 2014

Størrelse: px

Begynne med side:

Download "Elektronisk verifisering av legemiddelpakninger og status i Norge. Eckart Holtz 22.September 2014"

Sunniva Brekke
8 år siden
Visninger:

1 Elektronisk verifisering av legemiddelpakninger og status i Norge Eckart Holtz 22.September 2014

2 «unique identifier»

3 The (ESM) Fighting counterfeit medicines to ensure patient safety in Europe

4 Hovedpunkter Sikre at den legale forsyningskjeden for legemidler er beskyttet mot forfalskede legemidler. Securing the legal supply chain is key to tackle the growing threat of falsified medicines Forfalskningsdirektivet (FMD) med alle tiltak vil gjelde i EØS, teknisk implementering blir spesifisert. EU legislation to counter falsified medicines was adopted more than 2 years ago, technical implementation is now being specified MT-innehavere bærer kostnadene av fremtidig system MAHs will have to bear the cost of the future system Aktører i forsyningskjeden samarbeider om harmonisert, kostnadseffektivt og interessentstyrt system i overenstemmelse med lovgivningen og for å beskytte pasienten. Key supply chain partners proactively engaged in setting up a harmonised, costeffective, and stakeholder-governed system to comply with the legislation and ensure patient safety 4

EU legislation to counter falsified medicines was adopted more than 2 years ago, technical implementation is now being specified MT-innehavere bærer kostnadene av fremtidig system MAHs will have to

5 ESM Stakeholders 5

6 ESM Stakeholders......og i Norge: LMI Legemiddelindustrien Apotekforeningen Legemiddelgrossistforeningen Parallelldistributørforeningen 6

7 EU FALSIFIED MEDICINES DIRECTIVE New Legal Framework - ref. andre foredrag i dag

8 The Directive Safety Features What Does the Directive Mandate? What Will Be Decided by Implementing Measures? Safety features that enable relevant persons to verify authenticity identify individual packs Tamper evidence Rx included, all OTCs excluded Some exceptions based on a risk assessment Govts can use the system for reimbursement and/or pharmacovigilance purposes MAHs will pay for the repositories systems Characteristics & technical specifications of the unique identifier Criteria for the risk assessments & process for notification of products included Extent and modalities of verification of the safety features to ensure the verification of authenticity of each dispensed pack Establishment (including accessibility) of the repositories 8

Govts can use the system for reimbursement and/or pharmacovigilance purposes MAHs will pay for the repositories systems Characteristics & technical specifications of the unique identifier

9 EMVS DESIGN & ARCHITECTURE The Joint Stakeholder Proposal

Process Pharmaceutical Manufacturer Product Flow Wholesaler Wholesaler Pharmacist Patient Unique Serialisation with Random Numbers Voluntary Verification Verification upon Dispense

10 Process Pharmaceutical Manufacturer Product Flow Wholesaler Wholesaler Pharmacist Patient Unique Serialisation with Random Numbers Voluntary Verification Verification upon Dispense to Patient Upload Number GTIN Batch Expiry S/N Medicines Verification Repository Authenticate Number The key stakeholders all support the Point-of-Dispensing verification concept 10

to Patient Upload Number GTIN Batch Expiry S/N Medicines Verification Repository

11 DataMatrix The ESM uses a 2D barcode, developed to internationally recognised standards Four key data elements: 14 digit Manufacturer Product Code (GTIN or NTIN) Randomised Unique Serial Number Expiry Date Batch Number (up to 20 alphanumeric characters) Example: Product #: (01) Batch: (10)A1C2E3G4I5 Expiry: (17) S/N: (21)12345AZRQF

Serial Number Expiry Date Batch Number (up to 20 alphanumeric characters) Example: Product

Process - European Hub Pharmaceutical Manufacturer European Hub Parallel Distributor National System 1 National System n National Blueprint System 1 National Blueprint System n Pharmacy Wholesaler

12 Process - European Hub Pharmaceutical Manufacturer European Hub Parallel Distributor National System 1 National System n National Blueprint System 1 National Blueprint System n Pharmacy Wholesaler Pharmacy Wholesaler Wholesaler Pharmacy Wholesaler Pharmacy Parallel Distributor: mandatory verification + data upload Manufacturer: data upload + voluntary verification Periodic cross-region update Pharmacy: mandatory verification Wholesaler: voluntary verification 12

Pharmacy Wholesaler Pharmacy Parallel Distributor: mandatory verification + data upload Manufacturer: data upload +

13 Memorandum of Understanding (MoU) Guiding Policy Principles for Governance

Falsified Medicines Have elaborated and formally endorsed a

14 The MoU EAEPC, EFPIA, GIRP, and PGEU Have agreed a joint position paper Ten Core Principles to Protect Patients from Falsified Medicines Have elaborated and formally endorsed a Memorandum of Understanding providing the foundation for the pan-european system 14

15 NEXT STEPS

16 Between Now and 2018 Key milestones between now and an effective implementation of a harmonised, interoperable, and cost-effective EU serialisation system: ESM: Succesful implementation of EU-hub, national systems and nblueprint systems The EU Institutions: The publication of legal technical requirements in 2014 The EU/EEA Member States: The implementation by individual Member States (2018) 16

EU-hub, national systems and nblueprint systems The EU Institutions: The publication of legal

17 From: EU Commission P.Tosetti publication Jan.2014 Impact Assessment Outcome (I) Objective 1: to ensure efficient and effective characteristics and technical specifications of the unique identifier Selected option: Harmonisation of the composition of the number and the data carrier to fight against falsified, recalled and expired medicines The UI shall contain the following information: Manufacturer product code Serial number A national reimbursement number, if present Batch number Expiry date. The UI will be carried by a 2D barcode (data matrix). 17

unique identifier Selected option: Harmonisation of the composition of the number and the data carrier to fight against falsified,

18 From: EU Commission P.Tosetti publication Jan.2014 Impact Assessment Outcome (II) Objective 2: to introduce proportionate verification of the safety features in order to combat falsified medicines Selected option: Systematic verification of the safety features at the dispensing point and risk-based verification by wholesale distributors Medicines will be systematically checked-out at the dispensing point Wholesale distributors will verify the safety features when: The product is not obtained from the holder of the manufacturing authorisation or the holder of the marketing authorisation; The product is returned by another wholesale distributor or a pharmacy. 18

option: Systematic verification of the safety features at the dispensing point and risk-based verification by wholesale distributors Medicines will be systematically

19 From: EU Commission P.Tosetti publication Jan.2014 Impact Assessment Outcome (III) Objective 3: to ensure interoperability of the repository system, free movement of medicines and supervision by the competent authorities Selected option: Establishment and management by stakeholders with supervision by the relevant competent authorities 19

repository system, free movement of medicines and supervision by the competent

20 From: EU Commission P.Tosetti publication Jan.2014 In summary, the EU Commission will propose: Harmonization of the composition of the number and the data carrier Systematic verification of the safety features at the dispensing point and risk-based verification by wholesale distributors Establishment and management by stakeholders with supervision by the relevant competent authorities 20

and the data carrier Systematic verification of the safety features at the dispensing point and

21 Norsk felles forståelsesdokument («MoU») Basert på EU MoU og de ti hovedprinsippene Ferdigstilt i mai 2014 mellom de fire samarbeidspartene i Norge i Stakeholdergruppen Partene støtter dette dokumentet, formelle godkjenningsprosesser pågår MoU tilpasses hele forsyningskjeden og krever videre oppfølging 21

22 Norsk felles forståelsesdokument («MoU») Hva inneholder norsk MoU? 10 hovedprinsipper Systemarkitektur og eierskap Verifisering av pakninger, datatilgang og synlighet krav som skal inkorporeres i «Delegated Regulation» Systemets tilgjenglighet og bruk EMVO europeisk beslutningsorgan for e- verifisering Samhandling for e-verifisering i Norge (NMVO) 22

23 10 hovedprinsipper 1. Sikret salgspakning med et unikt serienummer 2. Sikkerhet gjennom hele legemiddelforsyningskjeden 3. Enhetlig verifiseringssystem 4. Verifiseringssystemer som fungerer sammen i hele EU/EØS 5. Verifisering og utregistrering av hver serialisert pakning 23

24 10 hovedprinsipper 6. Utnytte potensielle fordeler med verifiseringssystemet 7. Beskytte pasientdata og annen sensitiv informasjon 8. Enkle, robuste og kostnadseffektive sikkerhetstiltak 9. Samarbeid for å ivareta pasientens sikkerhet 10. Involvere alle aktører 24

25 Videre arbeid med implementering Ca. des.2014 «adoption of delegated acts/delegated regulation». Publisering i løpet av våren Trer i kraft etter 36 måneder (2018) På EU nivå: Dannelse av EMVO og endelig avklaring med generika produsenter På Norsk nivå: Involvering av alle relevante partnere og forberedelse av en norsk NMVO basert på Stakeholder gruppen. NMVO vil stå for alle kontrakter, IT-leverandørvalg for norsk nbps, forettingsplan, kostnader, etc.

26 Takk for oppmerksomheten! ensuring patients have access to safe medicines

Like dokumenter

2D-matriks på legemiddelpakninger

2D-matriks på legemiddelpakninger Sikkerhetsanordninger mot forfalskninger 29.April 2016 Info-møte Eckart Holtz, LMI 2D-matriks på Rx-legemiddelpakninger: Sikkerhetsanordninger mot forfalskninger - hva